FASN and ovarian cancer: For example, altered expression of enzymes [FA synthase (FASN)23, stearoyl-CoA desaturase-1 (SCD1)24, and lysophosphatidic acid acyltransferase-β (LPAAT-β)25] involved in the GP synthetic pathway was proposed as a potential indicator of the poor clinical outcome of ovarian cancer patients.